



Novel Therapeutic Inducible Exosome (iExo) Platform for Regenerative Medicine

Institute of Cellular and System Medicine &

Institute of Biotechnology and Pharmaceutical Research
National Health Research Institutes



Unmet Medical Need

INCIDENCE RATE OF PARKINSON'S DISEASE INCREASES IN THE U.S.

New Parkinson's Foundation-Backed Study Shows the Incidence of Parkinson's Disease (PD) in the U.S. Totals Nearly 90,000 Diagnoses Annually, a Rate 1.5 Times Higher Than Previous Estimates of 60,000 Diagnoses Annually

EVERY 6 MINUTES, SOMEONE IS DIAGNOSED WITH PD.



Old Estimate

Additional Diagnoses

New Estimate

NEW PD INCIDENCE IS 50% HIGHER THAN PREVIOUS ESTIMATES.

Each person in the chart represents 10,000 people diagnosed with PD each year.

PD INCIDENCE ESTIMATES ARE HIGHER IN MALES AS COMPARED TO FEMALES OF ALL AGES.







PD INCIDENCE RATES ARE HIGHER IN CERTAIN GEOGRAPHIC REGIONS.

- The "Rust Belt" (parts of the U.S. previously dominated by industrial manufacturing)
- Southern CaliforniaSoutheastern Texas
- Central Pennsylvania
- Central Fermisylvania
- Florida




1-800-4PD-INFO (473-4636) HELPLINE@PARKINSON.ORG

PARKINSON.ORG

- 5



Our Design for PD treatment



The degeneration of the dopaminergic neurons in the brain is thought to play a key role in the development of Parkinson's disease.

Our induced exosome (iExo) can potentiate the growth of dopamine neurons.



Product Profile

Key Features

- NHRI holds the design and synthesis of novel exosome inducers as such can direct the regulated sorting of relevant bioactive cargos into the collected exosomes
- Platform was implemented with Deep Learning/AI capacity

Pharmaceutical Development

Opportunity for large-scale bioproduction of inducible exosomes

Market Positioning

The iExo harness intrinsic stemness transferring from respective mesenchymal stem cells and such MSC-derived iExo can be employed as regeneration medicine for several unmet medical needs in area of brain associated diseases.